Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications patterns prevalence use vivelle® estraderm® oral premarin among women 45 years
… and rituximab increased to a peak of 31% in 2015, but its use had declined sharply by early 2016. Similarly, other … sharply to 25.8% by early 2016. Its use increased among both younger patients and those over age 65. This … are on the horizon for treatment of CLL, and treatment patterns are likely to continue shifting as treatment …
… most evident when we find differences across studies that use different data sources. Even in multidatabase studies, … we often still observe differences in the incidence and prevalence of health outcomes, medication use, and even … As a part of the DIVERSE initiative, a collaboration among members of the ISPE Databases Special Interest Group, …
… and other types of symptoms in patients with dementia. The prevalence is higher in Parkinson’s and Alzheimer’s disease … are used. Our objective was to describe diagnostic use to capture patients in studies published within the last 10 years. The main conclusions of our literature search are …
… Cross-Sectional Surveys to Assess Knowledge of Vaccines Among HCPs and Consumers OPPORTUNITY Our client needed to … milestones across the studies, while meeting deadlines for publications. OUR APPROACH We assembled a core team of …
… an in-clinic outcome assessment tool for ALS to remote-use at home. Panel 3: Patient Engagement at FDA March 1, … evaluation of clinical outcome assessment measures for use in clinical trials, as well as large scale epidemiologic …
… the framework eases discussions on the study design among stakeholders. Additionally, it helps avert biases that … pandemic, when some special populations (e.g., pregnant women) were underrepresented in randomized clinical trials …
… Publication Management and Medical Writing Publications are critical for the dissemination of your … and internal milestones is an integral part of the publications process. We develop a customized timeline for … following best practices. Our publication managers submit publications to journals across the spectrum of scientific …
… models (for example, to calculate quality-adjusted life years [QALYs] in cost-effectiveness analyses) or other … such as NICE, SMC, CDR, and PBAC), value messaging , and publications A Team Approach Let our multidisciplinary team …
… Measures Impact of Risk Minimization Measures on the Use of Cilostazol in Europe J Castellsague, B Calingaert , B … measures in 2013. After labeling changes, the annual prevalence of cilostazol decreased in all the study … populations. The highest reduction was 57% in Catalonia. Prevalence of smoking before initiation decreased only in …
… will last for 1 year and prices will become effective 2 years after that. The prices for the first round of 10 drugs … overall value of a product. Per the IRA, CMS “shall not use evidence from comparative clinical-effectiveness research … medical needs, and data on impacts to specific populations among other considerations This deadline is the day after CMS …